Nautilus Biotechnology, Inc. (NASDAQ:NAUT) to Post Q3 2022 Earnings of ($0.14) Per Share, Jefferies Financial Group Forecasts

Nautilus Biotechnology, Inc. (NASDAQ:NAUTGet Rating) – Stock analysts at Jefferies Financial Group raised their Q3 2022 EPS estimates for shares of Nautilus Biotechnology in a research note issued to investors on Wednesday, August 3rd. Jefferies Financial Group analyst B. Couillard now anticipates that the company will earn ($0.14) per share for the quarter, up from their prior estimate of ($0.16). The consensus estimate for Nautilus Biotechnology’s current full-year earnings is ($0.59) per share. Jefferies Financial Group also issued estimates for Nautilus Biotechnology’s Q4 2022 earnings at ($0.16) EPS, FY2022 earnings at ($0.54) EPS, Q1 2023 earnings at ($0.16) EPS, Q2 2023 earnings at ($0.17) EPS, Q3 2023 earnings at ($0.17) EPS, Q4 2023 earnings at ($0.17) EPS and FY2023 earnings at ($0.67) EPS.

Other research analysts also recently issued research reports about the stock. Morgan Stanley lowered their price objective on shares of Nautilus Biotechnology from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Wednesday. The Goldman Sachs Group lowered their target price on shares of Nautilus Biotechnology from $4.00 to $2.00 and set a “neutral” rating for the company in a report on Wednesday.

Nautilus Biotechnology Trading Up 4.3 %

NAUT opened at $2.94 on Friday. The company’s fifty day moving average price is $2.97 and its two-hundred day moving average price is $3.65. Nautilus Biotechnology has a 1-year low of $2.53 and a 1-year high of $8.61. The company has a market cap of $365.92 million, a price-to-earnings ratio of -5.64 and a beta of 0.96.

Nautilus Biotechnology (NASDAQ:NAUTGet Rating) last released its earnings results on Tuesday, May 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of large investors have recently modified their holdings of the company. Mirabella Financial Services LLP purchased a new stake in Nautilus Biotechnology in the fourth quarter valued at approximately $75,000. Shay Capital LLC purchased a new position in shares of Nautilus Biotechnology during the fourth quarter worth approximately $107,000. Affinity Asset Advisors LLC raised its stake in shares of Nautilus Biotechnology by 7.7% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,049,721 shares of the company’s stock worth $5,438,000 after acquiring an additional 74,721 shares in the last quarter. Tikvah Management LLC raised its stake in shares of Nautilus Biotechnology by 73.9% during the fourth quarter. Tikvah Management LLC now owns 1,231,835 shares of the company’s stock worth $6,381,000 after acquiring an additional 523,295 shares in the last quarter. Finally, Perceptive Advisors LLC raised its stake in shares of Nautilus Biotechnology by 2.2% during the fourth quarter. Perceptive Advisors LLC now owns 9,111,151 shares of the company’s stock worth $47,195,000 after acquiring an additional 200,000 shares in the last quarter. 47.89% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 50,000 shares of the business’s stock in a transaction on Monday, May 9th. The stock was purchased at an average price of $3.96 per share, for a total transaction of $198,000.00. Following the completion of the transaction, the chief executive officer now directly owns 9,964,488 shares of the company’s stock, valued at $39,459,372.48. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 41.30% of the company’s stock.

Nautilus Biotechnology Company Profile

(Get Rating)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

See Also

Earnings History and Estimates for Nautilus Biotechnology (NASDAQ:NAUT)

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.